Digital PET/CT Using [Ga-68]PSMA vs. [F-18]NaF for Evaluation of Osseous Metastatic Involvement in Prostate Cancer Patients

Completed

Conditions studied: Prostate Cancer

In brief

The purpose of this study is to evaluate a radioactive diagnostic study drug, which is called Gallium-68 Prostate Specific Membrane Antigen (\[Ga-68\]PSMA) for detection of bone metastasis in patients with prostate cancer. For imaging the investigators will use a FDA approved imaging technology, digital Positron Emission Tomography (PET/CT). The investigators would like to know if digital PET/CT using \[Ga-68\]PSMA provides accurate information about the extent of bone metastases. Therefore, the investigators will compare\[Ga-68\]PSMA PET/CT with Flourine-18 \[F-18\] Sodium Fluoride (NaF), which is a high resolution bone scan. \[F-18\]NaF is FDA approved and the reference standard for evaluating the presence of bone metastases.\[Ga-68\]PSMA is an investigational (experimental) drug that works by binding to Prostate Specific Membrane Antigen, which is overexpressed in prostate cancer. \[Ga-68\]PSMA is experimental because it is not approved by the Food and Drug Administration (FDA) at University Hospitals. However, FDA approval has been obtained for this study protocol by an Investigational New Drug (IND) application.

Key facts

Study ID

NCT05527483

Run by

University Hospitals Cleveland Medical Center

People needed

32

Starts

2022-04-21

Expected to finish

2022-10-10

Last updated by the study team

2024-05-16

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• 1) Patients must have a history of prostate cancer
• 2) Patients have known or highly suspected osseous metastatic involvement defined by the referring physician based on clinical history and/or findings from standard of care imaging.
• 3) Patients ≥ 18 years old
• 4) Patients able to tolerate PET/CT scans
• 5) Informed written consent must be given and signed

You may not qualify if…

• 1. Subjects who do not meet the noted inclusion criteria
• 2. Patients < 18 years old
• 3. Subjects who refuse to give or are unable to sign the informed consent
• 4. Anti-cancer treatment (chemotherapy and/or radiation therapy) within the last 2 weeks
• 5. Patients with a known allergy against Ga-68 PSMA or F-18 NaF

Where it is running

• Case Comprehensive Cancer Center — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.